In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.
Upon determination of eligibility, patients will be randomly assigned to one of two treatment arms: Docetaxel Docetaxel + Gemcitabine For ever 2 patients treated, 1 will receive treatment A (docetaxel) and 1 will receive treatment B (Docetaxel + Gemcitabine). The study is not blinded so both the patient and the doctor will know which treatment has been assigned.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
346
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
median survival
one-year survival.
toxicity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.